{"id":"kk8398","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By antagonizing the C5a receptor (C5aR1), KK8398 inhibits complement-mediated inflammation, which plays a key role in various inflammatory and autoimmune diseases. This mechanism reduces the chemotactic activity of C5a, thereby decreasing neutrophil and other immune cell infiltration into affected tissues and limiting downstream inflammatory cascades.","oneSentence":"KK8398 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 signaling pathway to reduce inflammatory cell recruitment and activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:57.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune/inflammatory conditions (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT06926491","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）","status":"RECRUITING","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2024-12-01","conditions":"Achondroplasia","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KK8398","genericName":"KK8398","companyName":"Kyowa Kirin Co., Ltd.","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KK8398 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 signaling pathway to reduce inflammatory cell recruitment and activation. Used for Autoimmune/inflammatory conditions (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}